LSTA · Lisata Therapeutics, Inc.
$1.67
-0.45 (-21.23%)
At close · Jul 24
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a period of twelve months after the date these consolidated financial statements are issued.”View the 10-Q filed May 11, 2026
Market Cap
$15.21M
Shares
9.11M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$170K
-83%
FY2025
Net Income
-$16.59M
+17%
FY2025
Gross Margin
11.73%
-4.9pp
FY2013
Operating Margin
-10711.18%
-8470.3pp
FY2025
Diluted EPS
-$1.91
+20.4%
FY2025
Operating Cash Flow
-$15.95M
+17.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $170K | $170K | $1M | $0 | $0 | — | — | — | — | — | $35.28M | $22.49M | $17.94M | $14.67M | $14.33M | $10.05M | $181.15K | |
| $32.95M | — | — | — | — | — | — | — | — | — | $31.14M | $20.16M | $15.68M | $12.95M | $11.95M | $8.65M | $0 | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $1.72M | $2.38M | $1.4M | $181.15K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 11.73% | 16.61% | 13.96% | 100% | |
| $6.55M | $7.95M | $11.33M | $12.73M | $13.07M | $17.68M | $9.25M | $10.8M | $7.59M | $15.84M | $16.7M | $23.9M | $29.19M | $16.92M | $10.45M | $7.72M | $6.01M | |
| — | $10.43M | $12.08M | $12.97M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $12.97M | $14.14M | $11.47M | $9.89M | $9.3M | $9.39M | $11.75M | $12.8M | $30.01M | $30.81M | $21.61M | $22.32M | $27.69M | $19.47M | |
| $48K | $65K | $71K | $71K | $21K | — | — | — | — | — | $570K | $605.2K | $605.2K | $605.2K | $605.2K | $577.3K | $35.2K | |
| $105K | $146K | $174K | $189K | $69K | $55K | $100K | $100K | $200K | $400K | $500K | $2.1M | $1.6M | $1M | $1M | $1.44M | $137.81K | |
| $17.47M | $18.38M | $23.41M | $25.71M | $57.6M | $29.05M | $19.15M | $20.09M | $16.99M | $27.59M | $29.5M | $136.34M | $75.68M | $51.48M | $44.72M | $35.41M | $26.03M | |
| -$17.3M | -$18.21M | -$22.41M | -$25.71M | -$57.6M | -$29.05M | -$19.15M | -$20.09M | -$16.99M | -$27.59M | -$29.5M | -$113.85M | -$57.74M | -$36.81M | -$30.39M | -$34M | -$25.85M | |
| — | -10711.18% | -2240.9% | — | — | — | — | — | — | — | -83.61% | -506.28% | -321.88% | -250.94% | -212.04% | -338.35% | -14272.2% | |
| -$17.2M | -$18.06M | -$22.24M | -$25.52M | -$57.53M | -$29M | -$19.05M | -$19.99M | -$16.79M | -$27.19M | -$29M | -$111.75M | -$56.14M | -$35.81M | -$29.39M | -$32.56M | -$25.72M | |
| — | — | — | — | — | — | — | $0 | $5000 | $378K | $1.78M | $2.13M | $755.7K | $281.42K | $1.58M | $2.65M | $289.53K | |
| $566K | $661K | $1.63M | $2.54M | $897K | $76K | $132K | $740K | $819K | -$105K | -$1.76M | $15.6M | $2.17M | -$1.9M | -$5.89M | -$561.82K | $44.09K | |
| — | $0 | -$130K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $24.93K | |
| -$16.74M | -$17.55M | -$20.78M | -$23.17M | -$56.7M | -$28.97M | -$19.01M | -$19.35M | -$16.17M | -$27.7M | -$31.26M | -$98.25M | -$55.57M | -$38.71M | -$36.28M | -$34.57M | -$25.81M | |
| -$387K | -$962K | -$798K | -$2.33M | -$2.48M | -$1.51M | -$10.87M | $0 | $0 | -$11.53M | $0 | -$17.24M | -$104.2K | $780.1K | -$175.53K | $0 | $0 | |
| -$16.35M | -$16.59M | -$19.99M | -$20.84M | -$54.23M | -$27.47M | -$8.15M | -$19.36M | -$16.17M | $22.98M | -$32.66M | -$81.01M | -$54.87M | -$38.98M | -$53.77M | -$47.13M | -$23.31M | |
| — | -9756.47% | -1998.5% | — | — | — | — | — | — | — | -92.55% | -360.25% | -305.89% | -265.75% | -375.23% | -469% | -12865.7% | |
| -$9.78M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$9.45M | $3.91M | |
| — | — | — | — | — | — | — | — | — | — | -$32.66M | -$80.89M | -$54.87M | -$38.98M | -$55.31M | -$47.77M | -$23.54M | |
| -$16.29M | -$16.54M | -$20.02M | -$20.85M | -$54.18M | -$27.52M | -$8.17M | -$19.33M | -$16.17M | $22.95M | -$32.66M | -$80.89M | -$54.87M | -$38.98M | -$52.06M | -$45.76M | -$21.83M | |
| USD/shares | — | -$1.91 | -$2.40 | -$2.58 | -$10.47 | -$7.45 | -$7.95 | — | -$25.05 | $38.40 | -$74.85 | — | — | — | — | — | — |
| USD/shares | — | -$1.91 | -$2.40 | -$2.58 | -$10.47 | -$7.45 | -$7.95 | — | — | $38.40 | -$74.85 | — | — | — | — | — | — |
| shares | — | 8.69M | 8.33M | 8.07M | 5.18M | 3.69M | 1.03M | 688.33K | 645.93K | 597.93K | 436.55K | — | — | — | — | — | — |
| shares | — | 8.69M | 8.33M | 8.07M | 5.18M | 3.69M | 1.03M | 688.33K | 645.93K | 597.93K | 436.55K | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2014: $550.67K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $170,000 | $1,000,000 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Royalty | $0 | $0 | $0 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$18,209,000 | -$22,409,000 | -$25,708,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment | -10711.2% | -2240.9% |